We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Enzyme Pair Identified as Target for Melanoma Chemotherapy

By LabMedica International staff writers
Posted on 07 Dec 2017
Print article
Image: A lymph node with almost complete replacement by metastatic melanoma. The brown pigment is focal deposition of melanin (Photo courtesy of Wikimedia Commons).
Image: A lymph node with almost complete replacement by metastatic melanoma. The brown pigment is focal deposition of melanin (Photo courtesy of Wikimedia Commons).
A team of cancer researchers has identified a pair of enzymes that they say could serve as therapeutic targets whose inhibition would block the growth of metastatic melanoma.

Bromodomain and extraterminal domain inhibitors (BETi) represent promising therapeutic agents for metastatic melanoma, yet their mechanism of action remains unclear. BET inhibitors are a class of drugs with anti-cancer, immunosuppressive, and other effects that are in clinical trials in the United States and Europe and are widely used in research. These molecules reversibly bind the bromodomains of bromodomain and extraterminal motif (BET) proteins BRD2, BRD3, BRD4, and BRDT, and prevent protein-protein interaction between BET proteins and acetylated histones and transcription factors.

Investigators at Mount Sinai School of Medicine (New York, NY, USA) reported in the November 16, 2017, issue of the journal Molecular Cell that they had identified AMIGO2 (Adhesion Molecule With Ig Like Domain 2), a transmembrane protein, as a BET target gene essential for melanoma cell survival. AMIGO2 was upregulated in melanoma cells and tissues compared to human melanocytes and nevi, and AMIGO2 silencing in melanoma cells induced G1/S arrest followed by apoptosis.

The investigators also reported that they had identified the pseudokinase PTK7 (Protein Tyrosine Kinase 7) as an AMIGO2 interactor whose function was regulated by AMIGO2. These results explained the mechanisms underlying the therapeutic effects of BETi in melanoma and suggested that the AMIGO2-PTK7 axis was a targetable pathway for treatment of metastatic melanoma.

"Melanoma is the most aggressive form of skin cancer, affecting more and more patients," said senior author, Dr. Emily Bernstein, associate professor of oncological sciences and dermatology at Mount Sinai School of Medicine. "While immunotherapy and targeted therapies have significantly improved the outcome for some metastatic melanoma patients, they have had success in a small subset of patients and can cause significant toxic side effects. Thus, their limitations underscore the need for new therapies, highlighting the importance of this research's discovery of novel targets."

Related Links:
Mount Sinai School of Medicine

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.